Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Executive Summary

Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.

You may also be interested in...



Merck Recasts Keytruda Regulatory Strategy In Head & Neck Cancer To Capitalize On KEYNOTE-048

Withdrawal of sBLA for full approval of Keytruda in second-line SCCHN makes way for Merck to file for first-line use. 

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.

The Year's Clinical Trials In Review: Big Misses In 2017

The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099197

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel